Compare NATL & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | CELC |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | NATL | CELC |
|---|---|---|
| Price | $37.74 | $102.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $42.75 | ★ $100.13 |
| AVG Volume (30 Days) | 446.1K | ★ 955.3K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,322,000,000.00 | N/A |
| Revenue This Year | $2.83 | N/A |
| Revenue Next Year | $3.96 | N/A |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | ★ 0.63 | N/A |
| 52 Week Low | $22.30 | $7.58 |
| 52 Week High | $42.23 | $108.91 |
| Indicator | NATL | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 70.63 |
| Support Level | $36.12 | $96.70 |
| Resistance Level | $37.61 | $108.91 |
| Average True Range (ATR) | 1.02 | 5.09 |
| MACD | 0.21 | -0.64 |
| Stochastic Oscillator | 95.11 | 65.62 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.